ACTRIMS 2023 | TSPO-PET imaging in MS clinical trials and treatment decisions

Laura Airas, MD, PhD, Turku University Hospital, University of Turku, Turku, Finland, discusses the importance of assessing the extent of the ongoing inflammatory component in multiple sclerosis (MS). Translocator protein-18 kDa (TSPO) positron emission tomography (PET) imaging could be very useful in identifying patients with smoldering inflammation that benefit the most from treatments targeting specifically microglial activation once these become available. Additionally, TSPO-PET imaging could be an excellent outcome measure in clinical trials addressing smoldering inflammation in progressive MS. This interview took place at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.